Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
UCB | Brussels | Healthcare | Pharmaceuticals | €35.29B | 147.9x | -5.17 | €186.60 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.3% Upside | Upgrade to Pro+ | |
Tubize-Fin | Brussels | Healthcare | Pharmaceuticals | €6.12B | 69.6x | €137.40 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.1% Upside | Upgrade to Pro+ | ||
Fagron | Brussels | Healthcare | Pharmaceuticals | €1.33B | 17.2x | 1.12 | €18.12 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.1% Upside | Upgrade to Pro+ | |
Hyloris | Brussels | Healthcare | Pharmaceuticals | €155.12M | -12.6x | 3.21 | €5.30 | -4.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biosenic | Brussels | Healthcare | Pharmaceuticals | €1.79M | -0.1x | -0.01 | €0.006 | 3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |